Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by HARRISON, G. G.
Right arrow Articles by MEISSNER, P. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HARRISON, G. G.
Right arrow Articles by MEISSNER, P. N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Journal of Anaesthesia, 1985, Vol. 57, No. 4 420-423
© 1985 The Board of Management and Trustees of the British Journal of Anaesthesia

research-article

PORPHYRINOGENICITY OF ETOMIDATE AND KETAMINE AS CONTINUOUS INFUSIONS

Screening in the DDC-primed Rat Model

G. G. HARRISON, M.D., F.F.A.R.C.S.(ENG.), M. R. MOORE, PH.D. and P. N. MEISSNER, B.SC.(MED.) (HONS.)

Department of Anaesthetics, University of Cape Town South Africa
MRC Liver Research Group, Department of Medicine, University of Cape Town and Gardiner Institute, Department of Medicine, Western Infirmary, University of Glasgow
MRC Liver Research Group, Department of Medicine, University of Cape Town and Groote Schuur Hospital South Africa

The porphyrinogenicity of etomidate and ketamine administered as continuous i.v. infusions was screened in the DDC-primed rat model of latent variegate porphyria. Ketamine produced no change from control in 5-aminolaevulinate synthase (ALAs) activity and haem intermediate production in either untreated or DDC-primed rats, and would appear to be safe for use in the patient with genetic porphyria. Etomidate, while producing no significant changes in these parameters in untreated rats, caused a statistically significant 47% increase in hepatic ALAs activity with a corroborative 85% increase in coproporphyrin and a 40% increase in protoporphyrin content, in DDC-primed rats. On these grounds, etomidate must be regarded as potentially porphyrinogenic when administered as a continuous infusion for total i. v. anaesthesia.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Br J AnaesthHome page
M. F. M. James and R. J. Hift
Porphyrias
Br. J. Anaesth., July 1, 2000; 85(1): 143 - 153.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.